Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more
Takeda Pharmaceutical Co. Ltd. (TKPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.046x
Based on the latest financial reports, Takeda Pharmaceutical Co. Ltd. (TKPHF) has a cash flow conversion efficiency ratio of 0.046x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($348.98 Billion) by net assets ($7.65 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Takeda Pharmaceutical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Takeda Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dell Technologies Inc
NYSE:DELL
|
-0.447x |
|
Nippon Telegraph & Telephone Corp
PINK:NPPXF
|
-0.002x |
|
AIRBNB INC. DL-01
F:6Z1
|
N/A |
|
Swiss Re AG
PINK:SSREF
|
0.058x |
|
Danone SA
PA:BN
|
0.095x |
|
United Rentals Inc
NYSE:URI
|
0.131x |
|
Comfort Systems USA Inc
NYSE:FIX
|
0.248x |
|
BASF SE NA O.N.
OTCQX:BFFAF
|
0.106x |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Co. Ltd. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Co. Ltd. from 2001 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.94 Trillion | $1.06 Trillion | 0.152x | +54.77% |
| 2024-03-31 | $7.27 Trillion | $716.34 Billion | 0.098x | -35.96% |
| 2023-03-31 | $6.35 Trillion | $977.16 Billion | 0.154x | -22.18% |
| 2022-03-31 | $5.68 Trillion | $1.12 Trillion | 0.198x | +1.20% |
| 2021-03-31 | $5.18 Trillion | $1.01 Trillion | 0.195x | +37.83% |
| 2020-03-31 | $4.73 Trillion | $669.75 Billion | 0.142x | +122.70% |
| 2019-03-31 | $5.16 Trillion | $328.48 Billion | 0.064x | -66.04% |
| 2018-03-31 | $2.02 Trillion | $377.85 Billion | 0.187x | +39.67% |
| 2017-03-31 | $1.95 Trillion | $261.36 Billion | 0.134x | +958.06% |
| 2016-03-31 | $2.01 Trillion | $25.49 Billion | 0.013x | -84.68% |
| 2015-03-31 | $2.21 Trillion | $182.52 Billion | 0.083x | +41.70% |
| 2014-03-31 | $2.54 Trillion | $148.34 Billion | 0.058x | -57.81% |
| 2013-03-31 | $2.22 Trillion | $307.71 Billion | 0.138x | -14.80% |
| 2012-03-31 | $2.07 Trillion | $336.57 Billion | 0.162x | +6.17% |
| 2011-03-31 | $2.14 Trillion | $326.94 Billion | 0.153x | -13.10% |
| 2010-03-31 | $2.16 Trillion | $381.17 Billion | 0.176x | +10.84% |
| 2009-03-31 | $2.05 Trillion | $326.27 Billion | 0.159x | +26.14% |
| 2008-03-31 | $2.32 Trillion | $292.50 Billion | 0.126x | +48.10% |
| 2007-03-31 | $2.46 Trillion | $209.28 Billion | 0.085x | -46.54% |
| 2006-03-31 | $2.35 Trillion | $373.57 Billion | 0.159x | +7.73% |
| 2005-03-31 | $2.00 Trillion | $295.54 Billion | 0.148x | -15.47% |
| 2004-03-31 | $1.78 Trillion | $311.12 Billion | 0.175x | +3.95% |
| 2003-03-31 | $1.57 Trillion | $263.45 Billion | 0.168x | +1.93% |
| 2002-03-31 | $1.46 Trillion | $240.59 Billion | 0.165x | -3.09% |
| 2001-03-31 | $1.25 Trillion | $212.66 Billion | 0.170x | -- |